Merck's IMPROVE-IT Study: Will Missing Data, Subgroups Hinder Zetia CV Claim?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks advisory committee to weigh impact of missing follow-up and 'notable differences' in subgroup treatment effects on company's request for broad cardiovascular benefit claim for Zetia and Vytorin.
You may also be interested in...
Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin
Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.
Califf’s Trial Design Prescription: Less Randomization, More Transparency
FDA’s new deputy commissioner is expected to advocate for innovation in clinical studies; Duke cardiologist has led numerous trials, including pivotal Xarelto study and Vytorin outcomes trial.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.